Filing Flows › Protagonist Therapeutics (PTGX) › Q3 2026 › vs Q2 2026
Protagonist Therapeutics (PTGX) Q3 2026 vs Q2 2026 (quarter over quarter)
Protagonist Therapeutics's revenue rose $60.9M (+29%) from $213M in Q2 2026 to $274M in Q3 2026. Operating margin 79.6% against 74.4% (+5.2 pts).
Protagonist Therapeutics, Q3 2026: revenue $274M (58× year over year), operating margin 79.6%, net earnings $220M, operating cash flow −$23.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 79.6% | 74.4% | +5.2 pts |
| Net margin | 80.2% | 76.3% | +3.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $274M | $213M | $60.9M | +29% |
| Other income, net | $8.2M | $6.3M | $1.9M | +30% |
| Operating profit | $218M | $159M | $59.6M | +38% |
| Costs & expenses | $56.1M | $54.7M | $1.4M | +3% |
| Pre-tax earnings | $227M | $165M | $61.5M | +37% |
| Research & development | $41.3M | $42.1M | −$787K | -2% |
| General & admin | $13.7M | $12.6M | $1.1M | +8% |
| Net earnings | $220M | $163M | $57.2M | +35% |
| Income tax | $6.6M | $2.3M | $4.3M | +189% |
| Operating cash sources | $258M | −$41.8M | $300M | — |
| Depreciation & amortization | $409K | $397K | $12K | +3% |
| Share-based compensation | $14.4M | $14.0M | $327K | +2% |
| Cash used in operations | $23.2M | −$219M | $242M | — |
| Working capital & other | $258M | −$41.8M | $300M | — |
Questions
How much did Protagonist Therapeutics's revenue grow quarter over quarter in Q3 2026?
Protagonist Therapeutics's revenue rose $60.9M (+29%) from $213M in Q2 2026 to $274M in Q3 2026. Operating margin 79.6% against 74.4% (+5.2 pts).